The two most frequent alterations in nonsmall cell lung cancer patients were epidermal growth factor receptor and KRAS mutations, accounting for 10%–40% and 25%–32%, respectively.
The two most frequent alterations in nonsmall cell lung cancer patients were epidermal growth factor receptor and KRAS mutations, accounting for 10%–40% and 25%–32%, respectively. Although the incidence rate is relatively low, other gene mutations including anaplastic lymphoma kinase fusion, MET ex14+, ROS1 fusion, KRAS mutation, and so forth, are also crucial to the survival of patients, and numerous significant pharmacological advances have been produced so far.